← Back to Search

Fedratinib for Myeloproliferative Disorders

Tampa, FL
Phase 1 & 2
Waitlist Available
Led By Taiga Nishihori, MD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2
Philadelphia chromosome negative myeloproliferative disease having undergone first allogeneic HCT with specific engraftment criteria
Must not have
Acute GVHD of the gut or liver currently on systemic therapy
Unable to swallow capsule
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether fedratinib can help keep MPN from coming back after HCT.

See full description
Who is the study for?
Adults with myeloproliferative neoplasms who've had a stem cell transplant can join this trial. They should be in good physical condition, understand the study, and follow its schedule. Women of childbearing age must test negative for pregnancy and use effective birth control; men must also practice safe sex or abstinence.Check my eligibility
What is being tested?
The trial is testing fedratinib pills as a maintenance therapy to prevent cancer from returning after a stem cell transplant. Participants will take the medication orally to see if it's effective and safe in maintaining their health post-transplant.See study design
What are the potential side effects?
Fedratinib may cause side effects like nausea, vomiting, diarrhea, liver problems, low blood counts leading to increased infection risk or bleeding issues. There might also be neurological symptoms such as confusion or difficulty coordinating movements.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am able to care for myself and perform daily activities.
 show original
Select...
I have a Philadelphia chromosome negative blood disorder and had a bone marrow transplant.
 show original
Select...
I am using approved contraception methods.
 show original
Select...
I am 18 years old or older.
 show original
Select...
My condition has not worsened according to specific health criteria.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently receiving treatment for acute GVHD affecting my gut or liver.
 show original
Select...
I cannot swallow pills.
 show original
Select...
I have been diagnosed with chronic liver disease.
 show original
Select...
I am currently receiving treatment for another cancer.
 show original
Select...
I am not taking medication that strongly activates CYP3A4.
 show original
Select...
I have a condition that affects how my body absorbs pills.
 show original
Select...
I have had Wernicke's encephalopathy in the past.
 show original
Select...
I am experiencing symptoms related to brain function issues.
 show original
Select...
I have not had major surgery in the last 28 days.
 show original
Select...
I have been diagnosed with HIV, Hepatitis B, or Hepatitis C.
 show original
Select...
I am currently fighting a serious infection.
 show original
Select...
I have heart failure that is not well-managed.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Phase 1: Recommended Phase 2 Dose
Phase 2: Progression Free Survival
Secondary study objectives
Number of Participants who develop Chronic Graft vs Host Disease
Overall Survival
Relapse Rate
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Phase 2: Treatment at Recommended Phase 2 Dose (RP2D)Experimental Treatment1 Intervention
Participants will take fedratinib at the dose determined in the phase 1 portion of this study, once daily by mouth.
Group II: Phase 1: Dose Level 3Experimental Treatment1 Intervention
Participants will take 400 mg fedratinib once daily by mouth.
Group III: Phase 1: Dose Level 2Experimental Treatment1 Intervention
Participants will take 300 mg fedratinib once daily by mouth.
Group IV: Phase 1: Dose Level 1Experimental Treatment1 Intervention
Participants will take 200 mg fedratinib once daily by mouth.

Find a Location

Closest Location:Moffitt Cancer Center· Tampa, FL· 825 miles

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
573 Previous Clinical Trials
144,984 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,712 Previous Clinical Trials
4,125,778 Total Patients Enrolled
Taiga Nishihori, MDPrincipal InvestigatorMoffitt Cancer Center
Hany Elmariah, MD, MSPrincipal InvestigatorMoffitt Cancer Center
2 Previous Clinical Trials
56 Total Patients Enrolled

Media Library

Fedratinib Clinical Trial Eligibility Overview. Trial Name: NCT05127174 — Phase 1 & 2
Myeloproliferative Neoplasms Research Study Groups: Phase 1: Dose Level 2, Phase 1: Dose Level 1, Phase 1: Dose Level 3, Phase 2: Treatment at Recommended Phase 2 Dose (RP2D)
Myeloproliferative Neoplasms Clinical Trial 2023: Fedratinib Highlights & Side Effects. Trial Name: NCT05127174 — Phase 1 & 2
Fedratinib 2023 Treatment Timeline for Medical Study. Trial Name: NCT05127174 — Phase 1 & 2
~3 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top